Clinical Trial

Testing Warning Labels for Retail Cannabis Products Using a Discrete Choice Experiment

Recruiting
View on ClinicalTrials.gov →
Summary
This discrete choice experiment (DCE) study aims to address gaps in cannabis packaging regulatory research by testing how variations in cannabis packaging and health warning design impact reactions to packaging and intentions about cannabis use. The goal of this work is to identify the most effective combination of health warning features to improve consumer awareness of cannabis health risks. Establishing criteria for cannabis products in the US is critical because inconsistent state guidelines have resulted in contradictory policies in legal retail states, arguably leading to increased hazardous use and failure to meet public health standards. The contributions of this study's outcomes are expected to be significant because they will benefit public health as cannabis becomes available in legal retail markets and regulatory and governmental agencies seek effective ways to communicate cannabis risks to the public.
Protocol Amendment History 3 changes
critical Phase changed: not specified -> not applicable 2026-07-28
notable Primary completion pushed: 2026-09-30 -> 2026-12-31 2026-07-19
minor Completion pushed: 2026-09-30 -> 2026-12-31 2026-07-19
Trial Details
NCT Number NCT07701304
Lead Sponsor University of Oklahoma
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Cannabis Use, Risk Perception, Decision Making
Enrollment 450 participants
Start Date 2026-05-19
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-27